Exelixis Partners with Merck for Stellar-316 Clinical Trial
Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and Canada, to supply Keytrude Qlex injection for subcutaneous administration in combination with zanzalintinib in Stellar-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer, CRC. Under the terms of the clinical development collaboration with Merck, Exelixis is sponsoring the Stellar-316 pivotal trial, and Merck will supply Keytrude Qlex.
